N/A N=8,476 Factors Contribute to Very Late Stent Thrombosis After New Generation DES Implantation in China
Stent Thrombosis
Primary: Very Late Stent Thrombosis — 92; 35 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=86 Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels
Coronary Artery Disease
Primary: In Stent Mean Cross-sectional Area of Neo-intimal Tissue Coverage — 1.381; 0.949 mm^2
Phase 4 N=208 Thromboaspiration in Patients With High Thrombotic Burden Undergoing Primary Percutaneous Coronary Intervention (PCI)
Primary PCI for STEMI
Primary: Rate of Complete ST-segment Elevation Resolution at 60 Minutes After the End of the Procedure — 38; 58 Participants
N/A N=222 EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions
Coronary Artery Disease (CAD) · Chronic Total Occlusion (CTO)
Primary: Number of Participants With Stent-related: Major Adverse Cardiac Events (MACE) (Per ITT Set) — 39 Participants
Phase 4 N=597 Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty
Saphenous Vein Graft Atherosclerosis
Primary: Number of Participants With Target Vessel Failure (TVF), Defined as the Composite of Cardiac Death — 16; 17 Participants
Phase 3 N=84 Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis
Coronary Artery Bypass
Primary: Prevalence of Intragraft Thrombus at 12-month Follow-up Optical Coherence Tomography Imaging — 14; 14 Participants — p=0.78
N/A N=1,398 Study Comparing the MiStent SES Versus the XIENCE EES Stent
Coronary Stenosis
Primary: Number of Participants With Occurrence of a Device Oriented Composite Endpoint (DOCE) — 40; 45 Participants
Phase 4 N=114 Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting
CVD
Primary: Number of Participants With Occlusion and Restenosis at One Year — 58; 56 participants
Phase 4 N=888 Clinical Investigation for Everolimus Drug Eluting Stent
Coronary Arterial Disease (CAD)
Primary: 888 Number of Participants With Major Adverse Cardiac Events (MACE) at 30 Days — 0 participants
N/A N=51 CVT-ISR First in Human Trial for Coronary In-Stent Restenosis
In-stent Restenosis
Primary: The Primary Safety Endpoint for the CVT-ISR Study: Freedom From Target Lesion Failure (TLF) Rate — 4; 1; 0; 3 Participants
N/A N=152 Post Market Surveillance Study of the Wingspan Stent System
Intracranial Atherosclerosis
Primary: Rate of Stroke or Death Among Participants — 4 Participants
Phase 4 N=250 Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
Saphenous Vein Graft Disease
Primary: Saphenous Vein Graft Occlusion — 17.4; 13.2 percentage of veins occluded
Phase 4 N=8,709 Randomized Study Comparing Endeavor With Cypher Stents (PROTECT)
Ischemic Heart Disease
Primary: To Compare Overall Definite or Probable Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System Versus the Cypher® Sirolimus-eluting Coronary…
N/A N=483 Perioperative Management of Patients With Coronary Stents Undergoing Noncardiac Surgery
Acute Coronary Syndrome · Coronary Stent Occlusion · Surgery
Primary: Major Adverse Cardiac and Cerebrovascular Events (MACCEs) — 63 participants
Phase 4 N=24 Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
Coronary Artery Disease
Primary: Change From Baseline in ADP-mediated Platelet Aggregation, APP, SFFLRN, AYPGKF. — 84; 38; 94; 53 % inhibitn of platelet aggregation — p=0.001
Phase 4 N=479 Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction
Myocardial Infarction
Primary: Device-oriented Composite Outcome — 12; 13 participants
N/A N=1,010 Efficacy of Long Term Plavix Therapy Post Angioplasty
Percutaneous Coronary Intervention
Primary: Number of Patients With Major Bleeding Need Transfusion — 7; 10 Participants
Phase 4 N=7,119 Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
Cardiovascular Disease · Interventional Cardiology
Primary: Number of Participants With BARC Type 2, 3, or 5 — 141; 250 Participants
N/A N=296 COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT
Coronary Artery Disease
Primary: Target Vessel Failure (TVF) — 11.38 percentage of participants
Phase 4 N=205 Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction
Acute Myocardial Infarction
Primary: Number of Patients With ST-segment Elevation Resolution Equal or More Than 50% — 47; 51 participants — p=0.56
Phase 3 N=451 Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis
Ischemic Stroke
Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…
Phase 4 N=60 Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)
Aortic Stenosis · Inflammation · Thrombosis
Primary: Platelet Reactivity — 275.5; 251; 234; 128.5 Platelet Reactivity Units
Phase 3 N=15,968 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation
Coronary Artery Disease (CAD)
Primary: Number of Participants With a Composite of All-cause Mortality or Non-fatal New Q-wave Myocardial Infarction (MI) — 304; 349 Participants
N/A N=50 Effects of Paclitaxel on Intimal Hyperplasia
Peripheral Vascular Disease
Primary: Evidence of Stenosis Lower Extremity Post Revascularization Using Ankle-Brachial Index Measurement at 10 Months — 0.93 ratio
N/A N=499 STELLAREX: ILLUMENATE Global and In-Stent Restenosis (ISR)
Peripheral Arterial Disease
Primary: Percentage of Participants With Freedom From Device and Procedure-related Death and Freedom From Target Limb Major Amputation and Clinically-driven Target Lesion…
Phase 2 N=535 Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
Myocardial Infarction · Acute Coronary Syndromes · Unstable Angina
Primary: The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding — 69; 60; 48 Participants
N/A N=57 Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project
Atherosclerosis of Native Arteries of the Extremities
Primary: Primary Patency — 94.4 percentage of lesions
N/A N=100 NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions
Atherosclerosis · Coronary Artery Disease
Primary: Technical Success Rate — 99.2 percentage of lesions
N/A N=963 XIENCE 28 Global Study
Bleeding Disorder · Stroke, Ischemic · Stroke Hemorrhagic
Primary: Number of Participants With Composite of Net Adverse Clinical Endpoint (NACE), by Propensity Score Quintiles — 2; 5; 10; 15 Participants
Phase 4 N=11,648 The Dual Antiplatelet Therapy Study (DAPT Study)
Coronary Artery Disease
Primary: MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT — 4.34; 5.92 percentage of patients (KM estimate) — p=<0.001